Know Cancer

forgot password

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

2 Years
Open (Enrolling)
Pheochromocytoma, Paraganglioma

Thank you

Trial Information

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Pheochromocytomas (PHEO) and paragangliomas (PGL) are rare tumors, with an incidence of 2-8
cases per million annually. These tumors develop in both children and adults. About 15-20%
metastasize. Chemotherapy for this tumor usually consists of a combination of
cyclophosphamide, vincristine, and dacarbazine delivered over two days and repeated every 3
weeks. Such combined chemotherapy is ineffective for the majority of patients with
metastatic PHEO/PGL. A few patients with malignant PHEO have experienced remissions with
sunitinib, but the drug may produce severe toxicity and the experience with that drug is
limited. Those patients who do experience a remission with chemotherapy must continue it
indefinitely to stay in remission. However, most such patients experience such severe side
effects from the chemotherapy (marrow suppression, neuropathy, etc) that their chemotherapy
must be discontinued. Thus, chemotherapy is either ineffective or intolerable for the vast
majority of patients with metastatic PHEO/PGL.

Inclusion Criteria:

- Diagnosis: Refractory or relapsed PHEO/PGL with original diagnosis based on tumor
histopathology or the finding of PHEO/PGL tumor cells in the bone marrow. The
diagnosis may also be based upon the presence of high plasma fractionated
metanephrines or high urine catecholamines/metanephrines with diagnostic MIBG uptake.

- Age: > 2 years and able to cooperate with radiation safety restrictions during
therapy period.

- Disease status: It must be determined that either the PHEO/PGL tumors are not
amenable to safe surgical resection or are metastatic. Disease evaluable by MIBG scan
must be present within 6 weeks of study entry and subsequent to any intervening

- Life Expectancy: greater than 3 months.

- Lanksy and Karnofsky Performance Status: 70% or higher.

- Prior Therapy: Patients may enter this study with or without having had other therapy
for recurrent tumor. Patients may be treated who have not had chemotherapy or
radiation therapy. Patients may also be treated who have failed to respond to
standard chemotherapy or radiation therapy. Patients must have fully recovered from
the toxic effects of any prior therapy. At least 2 weeks should have elapsed since
any anti-tumor therapy and the patient must meet hematologic criteria below. Three
months should have elapsed in the case of completing radiation to any of the
following fields: total craniospinal, total abdominal, whole lung, total body
irradiation). Cytokine therapy (eg G-CSF, GM-CSF, IL-6, erythropoietin) must be
discontinued a minimum of 24 hours prior to MIBG therapy. Prior 131I-MIBG therapy is
allowed if > 8 weeks from previous treatment. Cumulative lifetime dose of 131I-MIBG,
including the planned treatment, should not exceed 36 mCi/kg.

- Liver function: bilirubin < 2x upper limit of normal (ULN). Exception: Gilbert
syndrome); AST < 10x ULN.

- Kidney function: Creatinine =< 2x ULN.

- Hematopoietic Criteria Patients must have adequate hematopoietic function (without
transfusion): ANC >750 x 10E9/L; Platelets >50 x 10E9/L if stem cells are not
available; if stem cells are available, the patient should be independent of platelet
transfusions with a platelet count of at least 20 x 10E9/L. Hemoglobin >10g/dl at
time of treatment (transfusion allowed). Patients with granulocytopenia and/or
thrombocytopenia due to tumor metastatic to the bone marrow may be eligible after
discussion with Dr. Fitzgerald or designee.

- Normal lung function as manifested by no dyspnea at rest or exercise intolerance, no
oxygen requirement.

- No clinically significant cardiac dysfunction, normal EKG and EJ >50%

Exclusion Criteria:

- Patients with disease of any major organ system that would compromise their ability
to withstand therapy. Any significant organ impairment should be discussed with the
Study Chair or Vice Chair prior to patient entry.

- Patients with proteinuria in the absence of urinary infection 4 weeks prior to the
planned treatment date.

- Because of the teratogenic potential of the study medications, no patients who are
pregnant or breast feeding will be allowed. Patients of childbearing potential must
practice an effective method of birth control while participating on this study, to
avoid possible pregnancy.

- Patients who are on hemodialysis.

- Patients with active infections that meet grade 3-4 toxicity criteria.

Type of Study:

Expanded Access

Study Design:


Principal Investigator

Paul Fitzgerald, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of California, San Francisco


United States: Food and Drug Administration

Study ID:

CompUse MIBG Pheo



Start Date:

August 2009

Completion Date:

August 2021

Related Keywords:

  • Pheochromocytoma
  • Paraganglioma
  • Pheochromocytoma
  • Paraganglioma
  • MIBG
  • 131I-MIBG
  • Resistant
  • Relapsed
  • Treatment
  • UCSF
  • Pediatric
  • Adult
  • Oncology
  • Paraganglioma
  • Pheochromocytoma



UCSF San Francisco, California  941430324